Neoantigen Identification and Response to Adoptive Cell Transfer in Anti-PD-1 Naive and Experienced Patients with Metastatic Melanoma.

ABSTRACT:

Purpose

Immune checkpoint blockade (ICB) agents and adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL) are prominent immunotherapies used for the treatment of advanced melanoma. Both therapies rely on activation of lymphocytes that target shared tumor antigens or neoantigens. Recent analysis of patients with metastatic melanoma who underwent treatment with TIL ACT at the NCI demonstrated decreased responses in patients previously treated with anti-PD-1 agents. We aimed to find a basis for the difference in response rates between anti-PD-1 naïve and experienced patients.

Patients and methods

We examined the tumor mutational burden (TMB) of resected tumors and the repertoire of neoantigens targeted by autologous TIL in a cohort of 112 anti-PD-1 naïve and 69 a

SUBMITTER: Levi ST 

PROVIDER: S-EPMC9288495 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature